Mylan may have overcharged taxpayers $1.27 billion for EpiPen

Taxpayersmay have paid extra $1.27B for EpiPen
Posted at 8:54 AM, Jun 01, 2017
and last updated 2017-06-01 08:54:25-04

The pharmaceutical company behind the life-saving EpiPen allergy injection may have overcharged the federal government by more than $1 billion.

The Department of Health and Human Services wrote a letter to Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, to inform the committee that Mylan may have swindled $1.27 billion from taxpayers over the past 10 years.

Mylan is accused of incorrectly classifying the EpiPen as a generic drug instead of a brand name. This allowed the company to provide Medicaid less in rebates. Taxpayers ended up with a bigger bill.

Mylan is in the process of finalizing a $465 million settlement with the Department of Justice over the misclassification.

RELATEDMylan to pay $465M settlement over Medicaid EpiPen rebates